NCT02111317

A Study to Evaluate the Effect of Verapamil on the Pharmacokinetics of ASP015K in Healthy Adult Subjects

A Phase 1, Open-label, Single-Sequence, Crossover Drug Interaction Study to Evaluate the Effect of Verapamil on the Pharmacokinetics of ASP015K in Healthy Adult Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Astellas Pharma Global Development, Inc. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the effect of verapamil, a P-glycoprotein (P-gp) inhibitor, on the pharmacokinetics of ASP015K. This study will also assess the safety and tolerability of ASP015K administered alone and also and in combination with verapamil.

Detailed description

Eligible subjects will be admitted to the clinical unit on day -1 and remain confined until day 15.

Conditions

• Healthy Subjects
• Pharmacokinetics of ASP015K

Interventions

Type	Name	Description
DRUG	ASP015K	oral
DRUG	verapamil	oral

Timeline

• Start date: 2013-10-01
• Primary completion: 2013-11-01
• Completion: 2013-11-01
• First posted: 2014-04-11
• Last updated: 2014-04-11

Locations

1 site across 1 country: United States